Patients with hepatocellular carcinoma have very poor outcomes if diagnosed with advanced stage disease. Most patients with HCC have cirrhosis and therefore targeted surveillance can be considered. The aim of surveillance is to increase the proportion of patients diagnosed with early stage disease in who potentially curative treatments can be offered.

Biographies

Dr Tim Cross

Dr Cross qualified from St. Bartholomew's Hospital Medical School in 1996. He undertook general gastroenterology on the Northeast Thames rotation and underwent hepatology training, at Kings College Hospital, Addenbrooke’s Hospital Cambridge and the Royal Free Hospital. He was as a consultant in the Southwest Liver Unit, Plymouth before taking up a post in Liverpool in 2012.  He has an interest in hepatocellular carcinoma, prognostic models of liver disease, the impact of frailty on disease and translational research. He is also a past president of the British Association for the Study of the Liver (BASL).

Dr Ankur Srivastava

Dr Srivastava is a Consultant Gastroenterologist and Hepatologist at Southmead Hospital, North Bristol Trust. Having graduated from the University of Bristol, he completed his postgraduate training in the North East London training programme and completed his PhD at University College London. Dr Srivastava developed an interest in early detection of chronic liver disease and non-invasive liver fibrosis markers.